Henry Schein reported second-quarter results that exceeded Wall Street expectations, with revenue of $3.46 billion versus analyst estimates of $3.37 billion and adjusted EPS of $1.27 versus $1.24 expected. The company attributed the performance to accelerating internal sales growth and robust gains in its global dental merchandise segment. CEO Frederick Lowery highlighted success in converting occasional buyers into regular customers and strong market share gains in the US and Canada. The company slightly raised its full-year adjusted EPS guidance to $5.34 at the midpoint. During the earnings call, analysts questioned the sustainability of US dental consumables growth and the timing of value creation benefits. CFO Ronald South indicated most operating income improvements from these initiatives would materialise in the second half of the year.

Henry Schein reported second-quarter sales of $3.5 billion, up 6.7% year-over-year, driven by 4.6% internal local-currency growth and foreign exchange benefits. The healthcare distributor raised its full-year guidance following stronger-than-expected performance. GAAP net income rose to $94 million, or $0.82 per diluted share, from $86 million a year earlier. Non-GAAP earnings reached $1.27 per share, up 15.5% from $1.10 in the prior-year period. Operating margins expanded across all segments. GAAP operating margin increased 27 basis points to 4.94%, whilst non-GAAP operating margin grew 25 basis points to 7.21%. US dental merchandise sales climbed 8.3%, including 6.5% internal growth, with the company reporting market-share gains. Chief Executive Officer Fred Lowery attributed results to operational execution and early benefits from its value-creation programme.

Henry Schein (HSIC), a $9 billion healthcare distribution company, has underperformed the Nasdaq Composite despite recent gains. The stock is up 5.7% over three months, trailing the Nasdaq's 19.2% rise during the same period. Year-to-date, HSIC has gained 4.1% compared to the Nasdaq's 12.6% advance. The Melville, New York-based company, which supplies dental, medical and laboratory products to over one million customers, reported stronger-than-expected first-quarter results on 5 May. Adjusted earnings per share of $1.32 beat analyst estimates of $1.20, whilst revenue of $3.4 billion exceeded forecasts of $3.3 billion. Despite softer medical segment demand from a milder flu season, strength in Home Solutions and technology offerings offset the impact. The company expects full-year adjusted EPS between $5.23 and $5.37.